New Psychedelic Research Nonprofit Teams with Johns Hopkins University for Real-World Study on Use of Psilocybin MushrooPharmaDrug Inc. Enters into Definitive Agreement to Acquire First Smart Shop in the NetherlandsCybin Corp. Is A Multi-Faceted Life Sciences Company Investors Should Have On Their RadarMindleap Health™ Expands its Digital Mental Health Programs for Addiction, Psychedelic Integration and Holistic WellneNovamind Closes the Acquisition of Cedar Psychiatry, a Leading Psychedelic Therapy Organization in the U.S.Psychedelic Assisted Therapy Is Becoming A Very Real Alternative Method To Treat Mental IllnessNuminus and Together We Can Partner to Support Addiction Recovery and Mental WellnessMydecine Innovations Group Inc. Appoints Previous Red Bull Sports Marketing Director Jim Gunning as CMOGood2Go Corp. and Magical Brands Inc. Announce Update to Proposed Qualifying TransactionThe Psychedelic Legalization Movement Is In Full BloomNuminus Announces Short Form Prospectus Offering of Units for Gross Proceeds of up to $4.05 MillionNuminus Wellness Is Putting Key Pieces In Place To Drive Cutting Edge Research In The Field Of PsychedelicsMagicMed Industries Inc. Announces Brokered Private Placement with Mackie Research Capital CorporationCybin Corp. Announces Proposed Management Team and Board of Directors of the Resulting IssuerMydecine Innovations Group Inc. Announces NeuroPharm Inc. Commences PTSD Clinical Trial Initiative With Leading EuropeanWill Psychedelics Take The Same Trip Down The Road To Legalization As The Cannabis Industry?PharmaDrug Inc. Proposes a Strategic Mutual Investment with Red Light Holland Corp.Pure Extracts Has Significant Leverage To Both The Cannabis and Psychedelic SectorsRritual Mushrooms Is Here to Enhance You Daily “Ritual”MagicMed Industries Files First Psychedelic Derivative Patent
Back

Numinus Wellness (TSXV:NUMI) To Begin Trading Today On The TSX Venture Exchange

May 20, 2020 • 7:10 AM EDT
3 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

So far this year, the psychedelic industry has been a bright spot in what has been a challenging market. We like to compare the emergence of the psychedelic industry to the cannabis industry and believe that it is an opportunity to be aware of.

Many of the companies that are focused on the psychedelic industry are in process of developing treatments for debilitating mental illnesses. Although researchers have only scratched the surface when it comes to understanding the medical benefits that are associated with psychedelics, the initial data has been overwhelmingly positive, and we find this to be significant.

We have conducted significant due diligence on Numinus which aims to be one the first publicly traded companies licensed to test, sell and deliver psychedelic therapies. The company has been nothing short of an execution story and we are favorable on the direction that the management team is taking the business.

Today, Numinus will commence trading on the TSXV and will trade under the symbol NUMI.

We believe that Numinus represents a multi-faceted growth story and is an opportunity to be aware of. The company’s platform includes a testing and research facility that can leverage the development of psychedelic therapies to supplement existing options in addressing mental illness, addictions, and post-traumatic-stress disorder (PTSD). Numinus also has an established and fully integrated therapy and wellness center model that it plans to scale globally.

Numinus is led by a management team that has a proven track record of success in a number of industry and we find this to be of importance. The management team plans to fund growth through an existing revenue generating cannabis business and we find this to be an attractive aspect of the story.

Last summer, Numinus was issued a Dealer’s license under the Controlled Substances Act that allows it to play a key role in the areas of psychedelic substances research, testing, and global distribution. The company is approved to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT and mescaline. Going forward, Numinus plans to expand and is in the process of amending its license to include activities such as R&D, import/export and packaging/labelling.

Numinus plans on becoming the leading psychedelics drugs marketing and distribution company and is an opportunity to be closely following. If you are interested in learning more about Numinus, please send an email to support@mushroomstocks.com to be added to our distribution list.

 

 

 

 

 

 

 

Pursuant to an agreement between StoneBridge Partners LLC and Numinus Wellness Inc.. (NUMI) we have been hired for a period of 180 days beginning April 15, 2020 and ending October 15, 2020 to publicly disseminate information about (NUMI) including on the Website and other media including Facebook and Twitter. We are being paid $7,500 per month (NUMI) for or were paid “0” shares of restricted common shares. We own zero shares of (NUMI), which we purchased in the open market. We plan to sell the “ZERO” shares of (NUMI) that we hold during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (NUMI) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Share Share - Facebook Share - Twitter

Tags

Authored By

Michael Berger

Comments

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.
Subscribe
SUBSCRIBE NOW
close-link